SNT-5505 Market Summary

Key Factors Driving SNT-5505 Growth

1. First-in-class pan-lysyl oxidase (pan-LOX) inhibitor with disease-modifying potential

SNT-5505 (formerly PXS-5505) is an investigational, oral pan-lysyl oxidase (LOX/LOXL1-4) inhibitor being developed by Syntara for myelofibrosis (MF). Unlike approved JAK inhibitors that primarily improve splenomegaly and constitutional symptoms, SNT-5505 targets the excessive collagen cross-linking responsible for bone marrow fibrosis. By inhibiting all five lysyl oxidase enzymes, the drug is designed to remodel the bone marrow microenvironment, improve normal hematopoiesis, and potentially modify the underlying disease process, making it highly differentiated within the MF pipeline.

2. Positive Phase I/IIa and Phase II interim data support clinical differentiation

Results from the ongoing Phase I/IIa (PXS5505-MF-101) study demonstrated that SNT-5505 was generally well tolerated and showed encouraging biological activity, including improvements in bone marrow fibrosis grade, hemoglobin levels, platelet counts, spleen volume, and symptom burden. Interim Phase II data presented at the 2024 ASH Annual Meeting further suggested that the combination of SNT-5505 plus ruxolitinib produced progressive improvements in spleen volume reduction and symptom control over time while maintaining an acceptable safety profile. These findings support continued late-stage development and strengthen physician confidence in the program.

3. Combination strategy with ruxolitinib expands the commercial opportunity

Rather than replacing JAK inhibitors, SNT-5505 is being developed as an add-on therapy for patients with an inadequate response to ruxolitinib, the current standard of care. Since a large proportion of MF patients experience persistent symptoms or disease progression despite JAK inhibition, combination therapy represents a sizeable commercial opportunity. The ongoing add-on cohort evaluates SNT-5505 200 mg twice daily plus stable-dose ruxolitinib for up to 52 weeks, with endpoints including spleen volume reduction, symptom improvement, bone marrow fibrosis, platelet response, and overall clinical response.

4. Large unmet need for therapies that reverse bone marrow fibrosis

Although JAK inhibitors such as ruxolitinib improve symptoms, they have limited ability to reverse bone marrow fibrosis, and many patients discontinue treatment because of loss of efficacy or treatment-related cytopenias. Published clinical data indicate that approximately 75% of patients discontinue JAK inhibitor therapy within five years, and median survival after discontinuation is relatively poor. By directly targeting fibrosis and the bone marrow microenvironment, SNT-5505 has the potential to fill an important therapeutic gap and complement existing therapies rather than compete solely on symptom control.

SNT-5505 Recent Developments

In June 2025, the US FDA granted Fast Track designation to SNT-5505 for the treatment of myelofibrosis in patients with an inadequate response to JAK inhibitor therapy. Fast Track status enables more frequent interactions with the FDA, eligibility for rolling review and Priority Review, and the potential for an accelerated regulatory pathway.

“SNT-5505 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SNT-5505 for potential indication like Liver cancer, Myelodysplastic syndromes, Myelofibrosis, Myeloid leukaemia, and Breast cancer in the 7MM. A detailed picture of SNT-5505’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SNT-5505 for potential indications. The SNT-5505 market report provides insights about SNT-5505’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SNT-5505 performance, future market assessments inclusive of the SNT-5505 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SNT-5505 sales forecasts, along with factors driving its market.

SNT-5505 Drug Summary

SNT-5505 is an investigational, orally administered hematopoietic progenitor kinase 1 (HPK1/MAP4K1) inhibitor being developed for the treatment of myelofibrosis and other hematologic malignancies. SNT-5505 is designed to modulate immune and inflammatory signaling pathways that contribute to disease progression by inhibiting HPK1, a negative regulator of T-cell and other immune cell activation, with the goal of enhancing antitumor immunity while reducing the inflammatory microenvironment associated with myelofibrosis. Preclinical studies have demonstrated immunomodulatory and antitumor activity, and the drug is advancing through early-phase clinical evaluation to assess its safety, pharmacokinetics, and preliminary efficacy as both a monotherapy and in combination with established therapies such as JAK inhibitors. Early clinical experience suggests a manageable safety profile, with treatment-related adverse events primarily consisting of mild to moderate gastrointestinal symptoms, fatigue, and transient laboratory abnormalities. Although SNT-5505 has not yet received regulatory approval, it represents a novel investigational therapeutic approach that aims to complement existing myelofibrosis treatments by targeting immune-mediated mechanisms involved in disease pathogenesis. The report provides SNT-5505’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SNT-5505 Market Report

The report provides insights into:

• A comprehensive product overview including the SNT-5505 MoA, description, dosage and administration, research and development activities in potential indication like Liver cancer, Myelodysplastic syndromes, Myelofibrosis, Myeloid leukaemia, and Breast cancer.
• Elaborated details on SNT-5505 regulatory milestones and other development activities have been provided in SNT-5505 market report.
• The report also highlights SNT-5505‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The SNT-5505 market report also covers the patents information, generic entry and impact on cost cut.
• The SNT-5505 market report contains current and forecasted SNT-5505 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SNT-5505 market report also features the SWOT analysis with analyst views for SNT-5505 in potential indications.

Methodology

The SNT-5505 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SNT-5505 Analytical Perspective by DelveInsight

• In-depth SNT-5505 Market Assessment

This SNT-5505 sales market forecast report provides a detailed market assessment of SNT-5505 for potential indication like Liver cancer, Myelodysplastic syndromes, Myelofibrosis, Myeloid leukaemia, and Breast cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SNT-5505 sales data uptil 2034.

• SNT-5505 Clinical Assessment

The SNT-5505 market report provides the clinical trials information of SNT-5505 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SNT-5505 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SNT-5505 Market Potential & Revenue Forecast

• Projected market size for the SNT-5505 and its key indications
• Estimated SNT-5505 sales potential (SNT-5505 peak sales forecasts)
• SNT-5505 Pricing strategies and reimbursement landscape

SNT-5505 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SNT-5505 Market positioning compared to existing treatments
• SNT-5505 Strengths & weaknesses relative to competitors

SNT-5505 Regulatory & Commercial Milestones

• SNT-5505 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SNT-5505 Clinical Differentiation

• SNT-5505 Efficacy & safety advantages over existing drugs
• SNT-5505 Unique selling points

SNT-5505 Market Report Highlights

• In the coming years, the SNT-5505 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SNT-5505 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SNT-5505’s dominance.
• Other emerging products for Liver cancer, Myelodysplastic syndromes, Myelofibrosis, Myeloid leukaemia, and Breast cancer are expected to give tough market competition to SNT-5505 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SNT-5505 in potential indications.
• Analyse SNT-5505 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SNT-5505 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SNT-5505 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SNT-5505? How strong is SNT-5505’s clinical and commercial performance?
• What is SNT-5505’s clinical trial status in each individual indications such as Liver cancer, Myelodysplastic syndromes, Myelofibrosis, Myeloid leukaemia, and Breast cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SNT-5505 Manufacturers?
• What are the key designations that have been granted to SNT-5505 for potential indications? How are they going to impact SNT-5505’s penetration in various geographies?
• What is the current and forecasted SNT-5505 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SNT-5505 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SNT-5505 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is SNT-5505? What is the duration of therapy and what are the geographical variations in cost per patient?